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Objectives The aim of this study was to test whether c-Src tyrosine kinase mediates connexin-43 (Cx43) reduction and sud-
den cardiac death in a transgenic mouse model of cardiac-restricted overexpression of angiotensin-converting
enzyme (ACE8/8 mice).
Background Renin-angiotensin system activation is associated with an increased risk for arrhythmia and sudden cardiac
death, but the mechanism is not well understood. The up-regulation of c-Src by angiotensin II may result in the
reduction of Cx43, which impairs gap junction function and provides a substrate for arrhythmia.
Methods Wild-type and ACE8/8 mice with and without treatment with the c-Src inhibitor 1-(1,1-dimethylethyl)-1-(4-
methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (PP1) were studied. Telemetry monitoring, in vivo electro-
physiologic studies, Western blot analyses for total and phosphorylated c-Src and Cx43, immunohistochemistry
staining for Cx43, and functional assessment of Cx43 with fluorescent dye diffusion were performed.
Results The majority of the arrhythmic deaths resulted from ventricular tachycardia degenerating to ventricular fibrilla-
tion (83%). Levels of total and phosphorylated c-Src were increased and Cx43 reduced in ACE8/8 mice. PP1 re-
duced total and phosphorylated c-Src levels, increased Cx43 level by 2.1-fold (p  0.005), increased Cx43 at the
gap junctions (immunostaining), improved gap junctional communication (dye spread), and reduced ventricular
tachycardia inducibility and sudden cardiac death. The survival rate increased from 11% to 86% with 4 weeks of
PP1 treatment (p  0.005). Treatment with an inactive analog did not change survival or Cx43 levels.
Conclusions Renin-angiotensin system activation is associated with c-Src up-regulation, Cx43 loss, reduced myocyte coupling, and
arrhythmic sudden death, which can be prevented by c-Src inhibition. This suggests that an increase in c-Src activity
may help mediate renin-angiotensin system–induced arrhythmias and that c-Src inhibitors might exert antiarrhythmic
activity. (J Am Coll Cardiol 2011;58:2332–9) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.07.048w
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uThe renin-angiotensin system (RAS) is a key signaling path-
way, and the activation of that system is associated with an
increased incidence of cardiovascular death (1,2). In humans,
increased angiotensin II (Ang II) levels are associated with an
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Manuscript received June 6, 2011; accepted July 26, 2011.increased risk for ventricular arrhythmia (3), and treatment
ith an angiotensin-converting enzyme (ACE) inhibitor re-
uces that risk (4–8). Nevertheless, it is not completely
nderstood how RAS activation increases arrhythmic risk.
See page 2340
A critical component of the RAS is the ACE, which
cleaves the decapeptide angiotensin I to produce the 8
amino acid peptide Ang II, a central signaling molecule of
the RAS. Previously, we developed a transgenic mouse
model of RAS activation by overexpression of ACE re-
stricted to the heart (ACE8/8 mice) via replacement of the
somatic ACE promoter with the cardiac-specific alpha-
myosin heavy chain promoter (9). ACE8/8 mice are not
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normal left ventricular ejection fractions, and have no
ventricular fibrosis. They exhibit cardiac oxidative stress, a
high incidence of ventricular tachycardia (VT) and ventric-
ular fibrillation (VF), and subsequent sudden cardiac death
(SCD) associated with reduced ventricular connexin-43
(Cx43) levels (10). Treatment with ACE inhibitors and
Ang II receptor 1 blockers reduces the arrhythmic risk and
increases the Cx43 level (11). In the adult heart, ventricular
gap junctions are formed primarily by Cx43 protein. A
significant reduction in or lack of Cx43 can result in slow
conduction velocity and ventricular arrhythmia (12). The
molecular mechanism by which RAS activation causes the
decrease in Cx43 is unknown, however.
The tyrosine kinase c-Src has been linked primarily to tumor
growth, and the inhibition of c-Src has been shown to be
effective in controlling cancers (13–17). We have shown that in
an animal model of myocardial infarction, the up-regulation of
c-Src and an increase in the level of phosphorylated Tyr 416
c-Src (the active form of c-Src) result in the down-regulation
of Cx43 by competition between phosphorylated c-Src and
Cx43 for a binding site at zonula occludens–1, an intercalated
disk scaffolding protein (18). Elevated levels of reactive oxygen
species and Ang II can result in the up-regulation of c-Src
(19–21). We postulated that a cause of Cx43 reduction and
sudden death in ACE8/8 mice was an increased level of c-Src
and that the inhibition of c-Src would increase Cx43 and
improve survival in ACE8/8 mice.
Methods
The derivation and electrophysiological characterization of
ACE8/8 mice have been described previously (9,10), and it has
been shown by telemetry monitoring that the causes of SCD in
those animals are VT or VF, asystole, and slowed conduction
(10). We repeated telemetry monitoring for wild-type and
ACE8/8 mice in this study. Wild-type mice with and without
treatment with the c-Src inhibitor 1-(1,1-dimethylethyl)-1-(4-
methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (PP1),
ACE8/8 mice with and without treatment with PP1, and
ACE8/8 mice treated with 1-phenyl-1H-pyrazolo[3,4-d]-
pyrimidin-4-amine (PP3), an inactive analog of PP1, were
studied. The animal experiments were conducted according
to the National Institutes of Health Guide for the Care and
Use of Experimental Animals and were approved by the
University of Illinois Institutional Animal Care and Use
Committee. Mice of both sexes were treated with 1.5 mg/kg
PP1 (Enzo Life Sciences, Plymouth Meeting, Pennsylva-
nia), a specific inhibitor of c-Src tyrosine kinase, 3 times per
week for 4 consecutive weeks by intraperitoneal injection
(22–24). PP3 (Enzo Life Sciences) was administered intra-
peritoneally at the same dose (1.5 mg/kg twice weekly for 4
consecutive weeks). The treatment of all animals was
initiated when the mice were 30 days of age.
Telemetry monitoring and electrophysiologic study. Seven
ACE8/8 mice aged 5 weeks and 6 C57BL/6 control micewere implanted with ETA-F10
transmitters (Data Sciences In-
ternational, St. Paul, Minnesota).
Briefly, mice were anesthetized by
intraperitoneal injection of ket-
amine (100 mg/kg) and xylazine
(10 mg/kg) cocktail. A skin inci-
sion was made in the right abdom-
inal region, and a transmitter was
inserted subcutaneously to the left.
The 2 electrocardiographic leads
were tunneled and positioned
under the skin to generate a lead
II electrocardiographic configura-
tion. The skin incision was then
closed, and the animals were fol-
lowed by telemetry for a maximum
of 3 weeks or until their death.
Twenty-four hours after transmit-
ter implantation, electrocardio-
graphic signals recorded between
12 PM to 3 PM, when mice were
relatively calm and resting, were
used to calculate baseline heart rates. The electrocardio-
graphic signals immediately before death were analyzed for
rhythm changes. Heart rate calculations and cardiac rhythm
analysis were performed using Dataquest ART version 4.1
software (Data Sciences International).
For the electrophysiologic studies, the mice were anes-
thetized with an intraperitoneal injection of ketamine (100
mg/kg) and xylazine (5 mg/kg). After cut-down, a 1.1-F
catheter with 0.5-mm interelectrode spacing (EPR 800;
Millar Instruments, Houston, Texas) was placed into the
right jugular vein and advanced into the right ventricle. A
constant-current stimulator (A320, World Precision Instru-
ments, Sarasota, Florida) connected to a laptop computer
was used for cardiac stimulation. During the experiment,
body temperature was maintained at 37°C with a warming
pad. Burst pacing at cycle lengths of 100 to 50 ms was used
to test for VT inducibility. A rhythm with more than 3
consecutive ventricular beats was considered to be VT.
Western blot analysis. The mice were killed, and their
hearts were excised. The ventricular tissue was homogenized
in a buffer containing 20 mmol/l of tris-(hydroxymethyl)-
aminomethane (pH 7.4), 150 mmol/l of sodium chloride,
.5 mmol/l of ethylenediamine tetraacetic acid, 1% Triton-
00, 10 l/ml of phenylmethylsulfonyl fluoride, 10 l/ml of
rotein inhibitor cocktail (Pierce, Rockford, Illinois), and
0 l/ml of phosphatase inhibitor cocktail II (Sigma-
ldrich, St. Louis, Missouri). Protein samples (5 to 20 g)
were separated via 10% sodium dodecyl sulfate polyacryl-
amide gel electrophoresis and transferred to nitrocellulose
membranes. The membranes were blotted with the primary
antibodies against c-Src, phosphorylated (Tyr 416) c-Src,
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and Acronyms
ACE  angiotensin-
converting enzyme
Ang II  angiotensin II
Cx43  connexin-43
LY  Lucifer yellow
PP1  1-(1,1-dimethylethyl)-
1-(4-methylphenyl)-
1H-pyrazolo[3,4-d]
pyrimidin-4-amine
PP3  1-phenyl-1H-pyrazolo
[3,4-d]pyrimidin-4-amine
RAS  renin-angiotensin
system
SCD  sudden cardiac
death
TRD  Texas red dextran
VF  ventricular fibrillation
VT  ventricular
tachycardiaand Cx43 (Cell Signaling, Danvers, Massachusetts) and
b
w
t
s
(
c
t
F
f
w
o
w
0
b
T
c
F
t
r
(
A
s
s
p
i
d
l
s
i
s
m
e
n
T
w
2334 Sovari et al. JACC Vol. 58, No. 22, 2011
Src in Connexin-43 Remodeling and Arrhythmia November 22, 2011:2332–9ACE (Millipore, Temecula, California). For a loading
control, the membranes were blotted with a primary anti-
body against glyceraldehyde-3-phosphate dehydrogenase
(Santa Cruz Biotech, Santa Cruz, California). After treat-
ment with secondary antirabbit or antimouse antibodies,
imaging was performed with enhanced chemiluminescence.
The radiographic film images were scanned and analyzed
with ImageJ software (National Institutes of Health,
Bethesda, Maryland).
Immunohistochemistry. The mouse hearts were fixed in
10% formalin, after which 8-m-thick sections were
locked for 1 h at room temperature and then incubated
ith anti-Cx43 antibodies overnight at 4°C at concentra-
ions known to provide the best signal-to-noise ratio. The
lides were reviewed with a Zeiss Axioskop microscope
Carl Zeiss, Inc., Thornwood, New York), and photomi-
rographs with original magnification 40 were taken from
he apex, the mid left ventricle, and the left ventricular base.
rom each of those sites, photomicrographs were taken
rom the endocardium and epicardium. The Cx43 content
as quantified with the use of a grid that divided the field
f view into 200 squares. At the intersection points aligning
ith the intercalated disks, Cx43 was scored 1 (present) or
Figure 1 Survival Analysis, Telemetry Monitoring, and Inducibil
(A) Kaplan-Meier survival distribution analysis of ACE8/8 untreated mice, ACE8/8
ACE8/8 mice that received 1-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazolo[3,4
ment. PP1 treatment significantly reduced the rate of sudden cardiac death (SCD)
0.2 days in ACE8/8 mice treated with PP1 (n  22) (p  0.005, log-rank test). No
analog of PP1, did not increase the survival rate in ACE8/8 mice (11.2  1.2 day
rhythm preceding SCD: (top) ventricular tachycardia (VT) degenerating to ventricula
events resulted from ventricular tachyarrhythmia (83%). (C) Inducibility of VT was t
than 3 consecutive ventricular beats was considered to be VT. Examples of intrac
shown after 12 beats of burst pacing with a pacing cycle length of 50 ms. The VT
vs. 50%, p  0.05, n  20 and n  10, respectively). NSR  normal sinus rhythm(absent). The results were expressed as the percent occupied
y Cx43 in the total area examined, excluding pseudospaces.
his method has been used previously to quantify levels of
ollagen and Cx43 in cardiac tissue (25,26).
unctional assessment of Cx43. We used an established
echnique for measuring Cx43 function that involves fluo-
escent dye introduction and diffusion in intact heart muscle
27). Fresh hearts were obtained from wild-type, ACE8/8,
CE8/8 PP1-treated, and ACE8/8 PP3-treated mice. A
ample from each heart was placed in phosphate-buffered
aline at 37°C, the anterior surface of the left ventricle was
unctured with a 27-gauge needle, and the sample was
ncubated with a droplet of 0.5% Lucifer yellow (LY) and a
roplet of 0.5% Texas red dextran (TRD) in 150 mmol/l of
ithium chloride solution. After a 15-min incubation, the
amples were fixed in 4% formaldehyde for 30 min, washed
n phosphate-buffered saline, frozen in liquid nitrogen, and
liced into 14-m sections. The sections were mounted on
icroscope slides and examined on a Leica DM5000 B
pifluorescence microscope (Leica Microsystems Inc., Ban-
ockburn, Illinois). Digital images of the spread of LY and
RD were obtained. The measurement of the dye spread
as performed with ImageJ software. Molecules of TRD
VT
that received 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (PP3) treatment,
midin-4-amine (PP1) treatment, and wild-type (WT) mice that received PP1 treat-
mean survival time of 10.2  1.5 days in ACE8/8 mice (n  28) and 24.7 
hs happened in WT mice receiving PP1 treatment (n  14). PP3, the ineffective
0.2  1.5 days, p  NS, n  10). (B) Examples of telemetry recording of the
lation resulting in SCD and (bottom) severe bradycardia. The majority of SCD
using a 1.1-F catheter and an internal jugular vein access. A rhythm with more
electrograms of WT mice, ACE8/8 mice, and ACE8/8 mice treated with PP1 are
bility rate was statistically reduced with PP1 treatment in ACE8/8 mice (86.9%
 premature ventricular contraction.ity of
mice
-d]pyri
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with disrupted membranes. The TRD distribution was
subtracted from the length of the LY spread at the same site
to measure the true LY spread through gap junctions. Dye
spread in longitudinal and transverse directions was
assessed.
Statistical analysis. Data are expressed as mean  SEM.
The t test, 1-way analysis of variance with post hoc tests of
ignificance, the Tukey honestly significant test, and the
isher exact test for 2  2 tables were used as appropriate,
and p values 0.05 were considered statistically significant.
urvival data were analyzed using the Kaplan-Meier
ethod, and p values were calculated using log-rank
Figure 2 Western Blot Analysis of Protein Levels
All results are corrected for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) le
type (WT) mice (p  0.05), and the phosphorylated (Tyr 416) c-Src protein level w
(Cx43) level was reduced in ACE8/8 mouse hearts to 36% of the level in WT mou
(4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (PP1): 4 weeks of intraperiton
that in untreated ACE8/8 mice (p  0.05) and reduced the phosphorylated (Tyr 41
PP1 treatment resulted in a 2.1-fold increase in the Cx43 level in ACE8/8 mice an
groups). (C) The angiotensin-converting enzyme (ACE) level was increased 11.9-fo
not change the cardiac ACE level in ACE8/8 mice (p  NS). Treatment of WT anim
groups).tests. Correlations were assessed using Pearson correla-
tion coefficients.
Results
PP1 treatment prevents SCD and reduces VT inducibility.
Baseline heart rates were similar between the control and
ACE8/8 groups (548  17 beats/min vs. 491  34
beats/min, p  NS). All of the control mice survived until
the end of the telemetry follow-up. In contrast, 6 of 7
ACE8/8 mice died within 5 to 23 days (mean 10  3 days)
after transmitter implantation. Rhythm analysis showed
that 1 mouse died because of progressive bradycardia and 5
died because of VT degenerating to VF (Fig. 1). Treatment
) The total c-Src protein level was 1.47-fold higher in ACE8/8 mice than in wild-
-fold higher in ACE8/8 mice than in control mice (p  0.05). The connexin-43
rts (p  0.005, n  6 for all groups). (B) Treatment with 1-(1,1-dimethylethyl)-1-
jection of PP1 in ACE8/8 mice decreased the total c-Src protein level to 58% of
rc level to 75% of that in untreated ACE8/8 mice (p  0.05). More importantly,
eased the level of Cx43 to 68% of its normal level in WT mice (n  6 for all
CE8/8 mice compared with control animals (p  0.005). Treatment with PP1 did
th PP1 did not change significantly the total level of Cx43 (p  NS, n  6 for allvel. (A
as 2.6
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eal in
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ACE8/8 mice from 3 of 30 SCDs and a mean survival time
of 10.2  1.5 days to 20 of 23 SCDs and a mean survival
time of 24.7 0.2 days during the 30 days of treatment and
observation (p  0.005) (Fig. 1). The treatment of wild-
type mice with PP1 was not associated with any adverse
reaction. The treatment of ACE8/8 mice with PP3, the
inactive analog, did not result in a statistically significant
improvement in the survival rate compared with untreated
ACE 8/8 mice (11.2  1.2 days vs. 10.2  1.5 days, p 
NS). VT inducibility was observed in 3.3% of the wild-type
mice (n  30) and in 86.9% of the ACE8/8 mice (n  23)
(p  0.005). PP1-treated ACE8/8 mice showed a signifi-
Figure 3 Results of Immunostaining for Cx43
The connexin-43 (Cx43) level, which was measured as the ratio of stained area fo
mouse hearts than in wild-type (WT) mouse hearts (18.3  0.6% vs. 5.4  0.7%,
d]pyrimidin-4-amine (PP1) resulted in a 2-fold increase in the Cx43 level in ACE8/8
with the result of Western blotting and confirmed that the improvement in the Cx4
function, gap junctions. Treatment with 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amin
untreated ACE8/8 mice (5.4  0.7% vs. 6.5  1%, p  NS, n  4 for all groups)cant reduction in VT inducibility (86.9% vs. 50%, p 0.05)
(Fig. 1).
PP1 treatment reduces c-Src and raises Cx43 levels.
Western blot of the total and phosphorylated (Tyr 416) forms
of c-Src protein showed a 1.5-fold increase in the total c-Src
level and a 2.6-fold increase in the level of phosphorylated Src
protein in the hearts of ACE8/8 mice compared with those
levels in control hearts (p 0.05). In untreated ACE8/8 mice,
the level of Cx43 protein was 36% of its level in wild-type mice
(p 0.005) (Fig. 2A). In addition, the level of Cx43 was lower
in ACE8/8 mice with SCD compared with those animals that
did not experience SCD during the treatment time period
(57.8%, p  0.05). PP1 treatment in ACE8/8 mice reduced
in the field of view to the total field of view, was significantly lower in ACE8/8
.005). Treatment with 1-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazolo[3,4-
e hearts (p  0.005). The result of immunostaining for Cx43 was consistent
ein level was associated with the increased level of this protein at its site of
), the inactive analog of PP1, did not increase Cx43 level in comparison withr Cx43
p  0
mous
3 prot
e (PP3
.
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and 75%, respectively, of those levels in untreated ACE8/8
mice (p  0.05) (Fig. 2B). PP1 treatment also caused a
2.1-fold increase in the Cx43 protein level in treated ACE8/8
mice compared with untreated ACE8/8 mice (p  0.005).
The correlation between the levels of phosphorylated c-Src and
Cx43 was statistically significant in ACE8/8 mice (R 
0.85, p  0.05). Treatment of ACE8/8 mice with inactive
PP3 did not increase the total Cx43 protein level (p  NS).
Treatment of wild-type control mice with PP1 did not change
the total Cx43 level (Fig. 2C). Gene microarray analysis did
not show any statistically significant change in the messenger
ribonucleic acid abundances of Cx43. Treatment of ACE8/8
mice with PP1 did not decrease the ACE level (Fig. 2C).
Immunohistochemical analysis showed that the Cx43
level was significantly lower in the ACE8/8 untreated hearts
than in the wild-type hearts (5.4  0.7% vs. 18.3  0.6%,
Figure 4 Function of Gap Junctions Was Assessed by Modified
Lucifer yellow (LY; 400 kDa) spreads extensively through myocytes from wild-type
Overlay image (C). In the ACE8/8 mouse hearts, LY spread is decreased (D), with
pled in these ACE8/8 mouse hearts (F). Treatment of mice with 1-(1,1-dimethylet
spread (G) to well beyond TXD (H). Note that the overlay images from WT mice (C
cation of the overall dye spread shows that the overall dye spread in the ACE8/8
p  0.05) and that is restored to the normal level after PP1 treatment (0.21  0.
ACE8/8 mice, p  0.05). Analysis of the anisotropy of dye spread indicates that i
although more prominently in the longitudinal direction (K). Treatment of WT mice
all groups). ANOVA  analysis of variance. 0.005) (Fig. 3). PP1 treatment caused a 2.0-fold
increase in the Cx43 content in the ACE8/8 mouse hearts
(p  0.005). The extent of that improvement in the Cx43
level after PP1 treatment was consistent with the 2.1-fold
increase in the total protein level for Cx43 noted on
Western blot analysis. The immunostaining for Cx43
showed that the Cx43 level was increased at intercalated
disks. Treatment with the inactive analog PP3 did not
increase the Cx43 level at the gap junctions compared with
untreated ACE8/8 mice (p  NS).
c-Src inhibition improves gap junction function. Analy-
sis of dye spread as a functional measure of Cx43 activity
showed that LY migration in ACE 8/8 mice was 66% of
that in wild-type mice (0.14  0.01 mm vs. 0.21  0.02
mm, respectively, p  0.05), which indicates reduced gap
junction function in ACE8/8 mice (Fig. 4). Treatment with
the c-Src inhibitor PP1 restored gap junction function to
pe Loading
earts (A), far beyond the spread of Texas red dextran (TXD; 10,000 kDa) (B).
r cells coupled beyond TXD (E). Overlay image indicates that fewer cells are cou-
4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (PP1) restores normal dye
from PP1-treated mice (I) are similar in the extent of dye spread seen. Quantifi-
s significantly decreased (0.14  0.01 mm vs. 0.21  0.02 mm, respectively,
in WT mice vs. 0.20  0.02 mm in PP1-treated mice, p  NS; PP1-treated vs.
model, dye spread is lost in both the transverse and longitudinal directions,
P1 did not significantly change the gap junction conduction (p  NS, n  5 forScra
(WT) h
fewe
hyl)-1-(
) and
mice i
02 mm
n this
with P
2338 Sovari et al. JACC Vol. 58, No. 22, 2011
Src in Connexin-43 Remodeling and Arrhythmia November 22, 2011:2332–9that of wild-type mice (0.14  0.01 mm in ACE8/8 mice
vs. 0.21  0.02 mm in PP1-treated ACE8/8 mice, p 
0.05; wild-type vs. PP1, p  NS). The analysis of dye
spread in longitudinal and transverse directions separately
showed that the changes in dye spread were more promi-
nent in a longitudinal than in a transverse direction. This is
consistent with the immunohistochemical result that Cx43
increased most at the intercalated disks. PP3 had no
statistically significant effect on dye diffusion.
Discussion
The telemetry study showed that the mode of SCD in
ACE8/8 mice is mainly VT or VF and occasionally severe
bradyarrhythmia. This result confirms our previous telem-
etry recordings in these animals (10), and the observed
arrhythmias resulting in SCD are consistent with human
findings (28). The cardiac sodium channel generates the
main current for conduction, but ACE8/8 mice have no
significant change in their sodium current; however, their
levels of Cx43 are dramatically reduced (10). Cx43 is the
major protein of ventricular gap junctions that are low-
resistance conduits for electrical conduction in the heart. In
this study, we show that c-Src is up-regulated in these
animals and that it mediates the effect of Ang II in reducing
Cx43 and causing VT and VF (Fig. 5). That finding is
consistent with those of other investigators showing that
Ang II and oxidative stress up-regulate c-Src (19–21). In
addition, treatment with losartan, an Ang II type 1 receptor
blocker, reduces the active form of Src protein in ACE8/8
mice, supporting that the observed change in the level of Src
is due to the elevated level of Ang II and via the binding to
Figure 5 Schematic Figure of the Relation Between Ang II, c-S
c-Src mediates the effect of angiotensin II (Ang II) on connexin-43 (Cx43) reduction an
d]pyrimidin-4-amine (PP1) is a known specific inhibitor of c-Src tyrosine kinase that int
ATR-1  angiotensin II type 1 receptor; RAS  renin-angiotensin system; VF  ventricits type 1 receptor (Online Fig. 1). We have previously
shown that ACE 8/8 mice show cardiac oxidation, and this
might be 1 mechanism for the increase in activated c-Src.
c-Src can result in the reduction of the Cx43 level via its
competition with Cx43 for binding to zonula occludens–1.
Increased phosphorylated (Tyr 416) c-Src results in the
unbinding of Cx43 from gap junctions, diffusion away from
the intercalated disk, and enzymatic degradation (18). This
may not be the sole mechanism by which c-Src up-
regulation results in a reduction in Cx43. Nevertheless, the
effect of PP1 on the inhibition of c-Src, the increase in the
level of Cx43, and the statistically significant inverse corre-
lation between the levels of phosphorylated c-Src and Cx43
support a cause-effect relationship between the up-
regulation of c-Src and a reduction in Cx43. Cx43 ribonu-
cleic acid abundance was unchanged in ACE 8/8 mice and
with treatment, suggesting that the effects of c-Src and PP1
were post-transcriptional. The increased level of ACE in
ACE8/8 mice compared with the control animals did not
change with PP1 treatment, arguing that the effect of PP1
was downstream of RAS activation.
We showed that improvement in the total Cx43 level
occurred primarily at the intercalated disks and was correlated
with an improvement in gap junction function measured with
dye diffusion. The increase in Cx43 and the increase in the ease
of dye spread were associated with a reduced risk for VT
inducibility and sudden death. Cx43 reversal was not complete
in our study, but the changes noted were in a range consistent
with a significant reduction in sudden death. Homozygous
Cx43 knockout mice die from ventricular arrhythmia and
conduction blocks (12,29). Nevertheless, heterozygote
d Cx43
ired gap junction function. 1-(1,1-Dimethylethyl)-1-(4-methylphenyl)-1H-pyrazolo[3,4-
Ang II–mediated Cx43 reduction, myocyte uncoupling, and sudden arrhythmic death.
rillation; VT  ventricular tachycardia; ZO  zonula occludens.rc, an
d impa
errupts
ular fib
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not prone to ventricular arrhythmias and cardiac death (29),
which suggests that a reduction of more than 50% of the
normal level of Cx43 is required for electrical conduction to be
significantly impaired and cause arrhythmic death. In our case,
c-Src inhibition in ACE8/8 mice increased Cx43 levels from
36% to 68% and was associated with an improvement in
survival from 11% to 86% during the 4 weeks of treatment with
PP1. This is consistent with prior data in genetically altered
mice and with model predictions that the full restoration of
Cx43 levels is not necessary to achieve a significant therapeutic
effect (30).
Conclusions
RAS activation is associated with c-Src up-regulation, Cx43
loss, reduced myocyte coupling, and arrhythmic sudden
death. Those effects can be ameliorated by c-Src inhibition,
which suggests that an increase in c-Src activity may
participate in RAS-induced arrhythmias and that c-Src
inhibitors might exert antiarrhythmic activity in states of
RAS activation. Because we used a model of RAS activation
limited to the heart, results may vary with in vivo systemic
RAS activation.
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